By continuing to use our site, you agree to our Terms of Use and Privacy Policy. You can learn more about how we use cookies by reviewing our Privacy Policy.

I Agree
Presentations & Publications

LUM-201

ESPE 2023- The Hague,Netherlands – oral presentation 

Oral Presentation:
Late Breaking Oral Presentation: “Deconvolution Analysis:
Oral GH secretagogue (LUM-201) enhances growth in individuals with moderate Pediatric Growth Hormone Deficiency (PGHD) by enhancing endogenous GH secretion and increasing IGF-1”

September 23, 2023

Presenting Author
Fernando Cassorla, MD, University of Chile, Santiago, Chile

View the ESPE 2023 Presentation

ENDO 2023- Chicago, Illinois, USA – two oral presentations 

Oral Presentation:
“Response of Oral LUM-201 in OraGrowtH210 and OraGrowtH212 Trials in Idiopathic Pediatric Growth Hormone Deficiency (iPGHD): Combined Analysis Interim Analysis Data”

June  17, 2023

Presenting Author
Michael Tansey, MD, University of Iowa, Iowa City, Iowa USA

View the ENDO 2023 Presentation

Oral Presentation:
Dose Responsiveness of LUM-201 as Measured by Acute GH Response and IGF-1 and Annualized Height Velocity (AHV) Measured at 6 Months in the Interim Analysis of the OraGrowtH212 Study in Idiopathic Pediatric Growth Hormone Deficiency (iPGHD)”

June 17, 2023

Presenting Author
Fernando Cassorla, MD, University of Chile, Santiago, Chile

View the ENDO 2023 Presentation

PES 2023- San Diego, California, USA – oral presentation and poster

Oral Presentation:
“Growth Response to LUM-201 in the OraGrowtH210 Trial in Idiopathic Pediatric Growth Hormone Deficiency (iPGHD): Interim Analysis Data (41 subjects)”

May 7, 2023

Presenting Author
Andrew Dauber, MD, Childrens National Medical Center, Washington DC, USA

View the PES 2023 Presentation

Poster:
“Observed Serum IGF-1 Concentration Increase Within Normal Range After Prolonged Daily Oral LUM-201 Administration in Idiopathic Pediatric Growth Hormone Deficiency from the OraGrowtH212 Trial: Interim Analysis Data”

May 6, 2023

View the PES 2023 Poster


IMPE 2023- Buenos Aires, Argentina – oral presentation and poster

Oral Presentation:
Dose-dependent Increase in GH AUC0-12h with LUM- 201 in Idiopathic Pediatric GH Deficiency from the Interim Analysis Data of the OraGrowtH212 Trial”

March 5, 2023

Presenting Author
Fernando Cassorla, MD; University of Chile, Santiago, Chile

View the IMPE 2023 Presentation

Poster:
“LUM-201 in Idiopathic Pediatric Growth Hormone Deficiency (iPGHD) Interim Analysis on Baseline Demographics, Safety Profile and 6 month Annualized Height Velocity (AHV) from the OraGrowtH210 Trial”

March 5-7, 2023

Presenting Author
Alison Lunsford, MD, Texas Tech HSC, Amarillo, Texas, USA

View the IMPE 2023 Poster

IMPE 2023 Poster

ENDO 2021- virtually held meeting – poster

Poster: “LUM-201 Elicits Greater GH Response than Standard GH Secretagogues in Pediatric Growth Hormone Deficiency”

Presenting Author
George Bright, MD, Lumos Pharma, Austin, TX, USA.

 

PUBLICATIONS

LUM-201

 

Development of a Predictive Enrichment Marker for Oral GH Secretagogue LUM-201 in Children with Growth Hormone Deficiency

Authors

George M Bright, MD; Minh-Ha T Do, PhD; John C McKew, PhD; Werner F Blum, MD; Michael O Thorner, MB, BS, DSc

Journal of the Endocrine Society – bvab030

Published:  25 February 2021

 

Corroboration of Height Velocity Prediction Markers for rhGH with an Oral GH Secretagogue Treatment in Children with GHD

Authors

Werner F Blum, MD; George M Bright, MD; Minh-Ha T Do, PhD; John C McKew, PhD; Haiying Chen, MD, PhD; Michael O Thorner, MB, BS, DSc

Journal of the Endocrine Society – bvab029

Published:  25 February 2021

 

A GH Secretagogue Receptor Agonist (LUM-201) Elicits Greater GH Responses than Standard GH Secretagogues in Subjects of a Pediatric GH Deficiency Trial

Authors

George M Bright, MD; Michael O Thorner, MB, BS, DSc

Hormone Research in Pediatrics

DOI: 10.1159/000524244

Published:  30 March 2022